ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 前立腺癌の内分泌療法—気になる最新の動向
文献概要
要旨 内分泌療法として行われる去勢には外科的去勢と内科的去勢（LH-RHアゴニストおよびLH-RHアンタゴニスト）があり，去勢と抗アンドロゲン剤を併用するcombined androgen blockade（CAB）が本邦では広く用いられている。前立腺癌は内分泌療法にやがて抵抗性となり，去勢抵抗性前立腺癌となる。近年，アンドロゲンの合成阻害薬や第二世代の抗アンドロゲン剤が登場したことから，進行性前立腺癌の内分泌療法のストラテジーが変貌しつつある。抗アンドロゲン剤の作用機序をアンドロゲンレセプターの分子レベルで理解し，その耐性のメカニズムを理解することが，臨床的に抗アンドロゲン剤を有効に用いるために重要である。
参考文献
1）Labrie F, Dupont A, Belanger A, et al：Combination therapy with flutamide and castration（LHRH agonist or orchiectomy）in advanced prostate cancer：a marked improvement in response and survival. Journal of steroid biochemistry 23：833-841, 1985
2）Heidenreich A, Bastian PJ, Bellmunt J, et al：EAU guidelines on prostate cancer. Part Ⅱ：Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65：467-479, 2014
3）Hinotsu S, Akaza H, Usami M, et al：Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 37：775-781, 2007
4）PCTCC：Maximum androgen blockade in advanced prostate cancer：an overview of the randomised trials. Prostate Cancer Trialists'Collaborative Group. Lancet 355：1491-1498, 2000
5）Akaza H, Hinotsu S, Usami M, et al：Combined androgen blockade with bicalutamide for advanced prostate cancer：long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115：3437-3445, 2009
6）Matsuoka T, Kawai K, Kimura T, et al：Long-term outcomes of combined androgen blockade therapy in stage Ⅳ prostate cancer. J Cancer Res Clin Oncol, 2014[Epub ahead of print]
7）Loblaw DA, Virgo KS, Nam R, et al：Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer：2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25：1596-1605, 2007
8）Cookson MS, Lowrance WT, Murad MH, et al：Castration-Resistant Prostate Cancer：AUA Guideline Amendment. J Urol 193：491-499, 2014
9）McLeod DG, Iversen P, See WA, et al：Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97：247-254, 2006
10）Wirth M, Tyrrell C, Wallace M, et al：Bicalutamide（Casodex）150mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58：146-151, 2001
11）Tyrrell CJ, Kaisary AV, Iversen P, et al：A randomised comparison of‘Casodex’（bicalutamide）150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33：447-456, 1998
12）Iversen P：Bicalutamide monotherapy for early stage prostate cancer：an update. J Urol 170：S48-52；discussion S52-44, 2003
13）Kelly WK and Scher HI：Prostate specific antigen decline after antiandrogen withdrawal：the flutamide withdrawal syndrome. J Urol 149：607-609, 1993
14）Small EJ and Carroll PR：Prostate-specific antigen decline after casodex withdrawal：evidence for an antiandrogen withdrawal syndrome. Urology 43：408-410, 1994
15）Akakura K, Akimoto S, Ohki T, et al：Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45：700-704；discussion 704-705, 1995
16）Kojima S, Suzuki H, Akakura K, et al：Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171：679-683, 2004
17）Suzuki H, Okihara K, Miyake H, et al：Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180：921-927, 2008
18）Miyamoto H, Rahman MM and Chang C：Molecular basis for the antiandrogen withdrawal syndrome. Journal of cellular biochemistry 91：3-12, 2004
19）Gottlieb B, Beitel LK, Nadarajah A, et al：The androgen receptor gene mutations database：2012 update. Human mutation 33：887-894, 2012
20）Suzuki H, Akakura K, Komiya A, et al：Codon 877 mutation in the androgen receptor gene in advanced prostate cancer：relation to antiandrogen withdrawal syndrome. The Prostate 29：153-158, 1996
21）Hara T, Miyazaki J, Araki H, et al：Novel mutations of androgen receptor：a possible mechanism of bicalutamide withdrawal syndrome. Cancer research 63：149-153, 2003
22）Terada N, Shimizu Y, Yoshida T, et al：Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. The Prostate 70：252-261, 2010
23）Zhao XY, Malloy PJ, Krishnan AV, et al：Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature medicine 6：703-706, 2000
24）Balbas MD, Evans MJ, Hosfield DJ, et al：Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2：e00499, 2013
25）Veldscholte J, Berrevoets CA, Brinkmann AO, et al：Anti-androgens and the mutated androgen receptor of LNCaP cells：differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31：2393-2399, 1992
26）Korpal M, Korn JM, Gao X, et al：An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100（enzalutamide）. Cancer discovery 3：1030-1043, 2013
27）Narimoto K, Mizokami A, Izumi K, et al：Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. International journal of urology：official journal of the Japanese Urological Association 17：337-345, 2010
28）Hu R, Dunn TA, Wei S, et al：Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer research 69：16-22, 2009
29）Antonarakis ES, Lu C, Wang H, et al：AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371：1028-1038, 2014
30）Efstathiou E, Titus M, Wen S, et al：Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. Eur Urol 67：53-60, 2015
掲載誌情報
